The findings supported the National Institute on Aging-Alzheimer’s Association (NIA-AA) research framework for Alzheimer’s disease, which is based on biomarkers of amyloid, tau, and neurodegeneration.

Since 1972, clinicians have used the Cookie Theft image to assist them diagnose speech and language problems as well as spatial and visual anomalies. However, a position presented in the Journal of the American Medical Association – Neurology suggests that frequent exposure to the Cookie Theft image may reduce patients’ self-confidence and undermine their sense of belonging and trust.

Results of a study published online ahead of print in Science Advances suggest that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may hijack tunneling nanotubes to enter the brain and induce neurological symptoms.

The update, which was presented during a panel discussion at the Alzheimer Association International Conference 2022 (AAIC2022) in San Diego, CA, is based on evidence from real-world use of aducanumab and is intended to improve risk mitigation, safety monitoring, patient selection, and shared decision-making.

In what is thought to be the largest study to date of any type of ketamine treatment, the findings revealed that, after four sessions, 89 percent of participants reported improvement in their depression and/or anxiety symptoms. On the PHQ-9 or GAD-7 scale, 63 percent of participants saw a 50% or greater improvement. PHQ-9 remission rates were 32.6 percent and GAD-7 remission rates were 31.3 percent. Furthermore, at the end of the four weeks, 62 percent of patients who had suicidal ideation prior to treatment reported no suicidal ideation.

The potential link between insulin resistance and bipolar disorder is causing a “paradigm shift in psychiatry,” remarked Dr. Cynthia Calkinan, associate professor of psychiatry at Dalhousie University in Halifax, Nova Scotia, Canada.